AstraZeneca’s Breakthrough in COVID-19 Protection for High-Risk Patients
Company Announcements

AstraZeneca’s Breakthrough in COVID-19 Protection for High-Risk Patients

AstraZeneca plc (GB:AZN) has released an update.

AstraZeneca’s SUPERNOVA Phase III trial has yielded positive results, showing that its investigational long-acting antibody, sipavibart, significantly reduces symptomatic COVID-19 in immunocompromised patients. This large global trial provides the first efficacy data for a COVID-19 antibody against recent SARS-CoV-2 variants in a group that includes blood cancer patients and organ transplant recipients, among others. With the immunocompromised constituting a substantial portion of severe COVID-19 cases, sipavibart offers a promising preventive treatment for this vulnerable population.

For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAstraZeneca reports China President currently under investigation
TipRanks UK Auto-Generated NewsdeskAstraZeneca’s China Operations Amid Leadership Investigation
TheFlyAstraZeneca’s Fasenra approved in EU for EGPA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App